



## Review Special Issue Series: T-cell Based Vaccine Development against Pathogen Infections

Guest Editor:

**Prof. Dr. Zheng Zhang**

Shenzhen Third People's Hospital, Second Hospital  
Affiliated to Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen 518112, China

Deadline for manuscript submissions:

**31 December 2024**

### Message from the Guest Editor

Current COVID-19 vaccines are designed to induce neutralizing antibodies against SARSCoV-2, which wane over time and are usually evaded by highly infectious variants such as Omicron. SARS-CoV-2-specific T cells induced during infection or vaccination largely maintained their reactivity to viral variants, including Omicron, indicating T cell responses are critical for long-term protective immunity. Thus, the development of T-cell-based vaccines that are able to induce long-term memory T cells might be a reasonable and effective strategy to provide persistent protection against constantly mutating viruses, including SARS-CoV-2.

This Special Issue will broadly cover the topics related to T-cell-based vaccines. The interests of this Special Issue include, but are not limited to: (1) dynamics and functionality of T cell response to viruses including SARS-CoV-2 (2) dominant T cell epitopes in various viruses such as SARS-CoV-2 (3) generation and maintenance of long-term memory T cells, and (4) animal models for evaluation of the immunogenicity and efficacy of T-cell-based vaccines designed for humans.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)